Long term management of idiopathic pulmonary fibrosis using non-invasive and cpap oxygen therapy
Respiratory Ventilatory Strategies in Acute and Chronic Respiratory Failure in Idiopathic Pulmonary Diseases: A Practical Approach, NOVA Publications , ss.311-316, 2020
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2020
- Yayınevi: NOVA Publications
- Sayfa Sayıları: ss.311-316
- Anahtar Kelimeler: CPAP, Domiciliary non-invasive ventilation, High flow oxygen, Interstitial lung disease, Long term oxygen therapy, Management of idiopathic pulmonary fibrosis, Prognosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Over the last decade advances in pulmonary radiology have led to an increased familiarity of interstitial lung disease (ILD). Among the ILDs, idiopathic pulmonary fibrosis (IPF) is the most studied in terms of basic pharmaceutical research. Following diagnosis, disease progression can be slowed and quality of life can be improved, however, despite the availability of promising new drugs, life expectancy is still 3 to 5 years after diagnosis. There is still no definitive evidence regarding the effect of long term oxygen therapy (LTOT) on prolonged survival of patients with IPF although patients mostly opt to use LTOT as it improves their level of comfort. Even acute state, high flow oxygen with a nasal cannula (HFO-NC) provides promising results with respect to patient's comfort and allowing them to feel better in their last days of life in hospital. Domiciliary continuous positive airway pressure (CPAP) and non-invasive mechanical ventilation (NIV) can provide respiratory support in the advanced stages of IPF. CPAP with LTOT shows a similar effect to that of HFO-NC. NIV can be helpful if in cases with hypercapnia. Regardless of this respiratory support, the involvement of lung parenchyma determines the outcome. In this review, the long term management of IPF with LTOT and CPAP/NIV are evaluated.